(Q40106296)

17 September 2017

title

Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib (English)

1 reference

17 September 2017

main subject

hepatocellular carcinoma

1 reference

Sadahisa Ogasawara

1

1 reference

17 September 2017

Tetsuhiro Chiba

2

1 reference

17 September 2017

Yoshihiko Ooka

3

1 reference

17 September 2017

Eiichiro Suzuki

4

1 reference

17 September 2017

Naoya Kanogawa

5

1 reference

17 September 2017

Tomoko Saito

6

1 reference

17 September 2017

Tenyu Motoyama

7

1 reference

17 September 2017

Akinobu Tawada

8

1 reference

17 September 2017

Fumihiko Kanai

9

1 reference

17 September 2017

Osamu Yokosuka

10

1 reference

17 September 2017

publication date

14 January 2016

1 reference

Investigational New Drugs

17 September 2017

published in

1 reference

17 September 2017

volume

34

1 reference

17 September 2017

issue

2

1 reference

17 September 2017

page(s)

255-260

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-016-0323-1

17 September 2017

exact match

0 references

cites work

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Heterogeneity in cancer: cancer stem cells versus clonal evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0323-1

10.1007/S10637-016-0323-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

17 September 2017

1035505801

0 references

1 reference